KR20160002709A - 초고순도 테트라하이드로카나비놀-11-오익산 - Google Patents

초고순도 테트라하이드로카나비놀-11-오익산 Download PDF

Info

Publication number
KR20160002709A
KR20160002709A KR1020157024773A KR20157024773A KR20160002709A KR 20160002709 A KR20160002709 A KR 20160002709A KR 1020157024773 A KR1020157024773 A KR 1020157024773A KR 20157024773 A KR20157024773 A KR 20157024773A KR 20160002709 A KR20160002709 A KR 20160002709A
Authority
KR
South Korea
Prior art keywords
acid
fold
receptor
affinity
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020157024773A
Other languages
English (en)
Korean (ko)
Inventor
마크 테퍼
Original Assignee
코버스 파마수티컬스, 아이엔씨.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 코버스 파마수티컬스, 아이엔씨. filed Critical 코버스 파마수티컬스, 아이엔씨.
Publication of KR20160002709A publication Critical patent/KR20160002709A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Medicinal Preparation (AREA)
KR1020157024773A 2013-02-12 2014-02-12 초고순도 테트라하이드로카나비놀-11-오익산 Ceased KR20160002709A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361763630P 2013-02-12 2013-02-12
US61/763,630 2013-02-12
US201361837743P 2013-06-21 2013-06-21
US61/837,743 2013-06-21
PCT/US2014/016050 WO2014127016A2 (en) 2013-02-12 2014-02-12 Ultrapure tetrahydrocannabinol-11-oic acids

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020197036267A Division KR20190139327A (ko) 2013-02-12 2014-02-12 초고순도 테트라하이드로카나비놀-11-오익산

Publications (1)

Publication Number Publication Date
KR20160002709A true KR20160002709A (ko) 2016-01-08

Family

ID=51354671

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020157024773A Ceased KR20160002709A (ko) 2013-02-12 2014-02-12 초고순도 테트라하이드로카나비놀-11-오익산
KR1020197036267A Ceased KR20190139327A (ko) 2013-02-12 2014-02-12 초고순도 테트라하이드로카나비놀-11-오익산

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020197036267A Ceased KR20190139327A (ko) 2013-02-12 2014-02-12 초고순도 테트라하이드로카나비놀-11-오익산

Country Status (9)

Country Link
US (8) US20150141501A1 (enExample)
EP (2) EP2956133A4 (enExample)
JP (3) JP6689078B2 (enExample)
KR (2) KR20160002709A (enExample)
CN (2) CN105228613A (enExample)
AU (2) AU2014216440B2 (enExample)
BR (1) BR112015019180A8 (enExample)
CA (1) CA2900982C (enExample)
WO (1) WO2014127016A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6689078B2 (ja) 2013-02-12 2020-04-28 コーバス ファーマシューティカルズ インク． 超高純度なテトラヒドロカンナビノール−１１−酸
US20190133995A1 (en) * 2016-04-29 2019-05-09 Corbus Pharmaceuticals, Inc. Methods for the treatment of infection
EP3481371A1 (en) * 2016-07-11 2019-05-15 Intec Pharma Ltd. Oral gastroretentive formulations and uses thereof
US10239808B1 (en) 2016-12-07 2019-03-26 Canopy Holdings, LLC Cannabis extracts
EP3745884A1 (en) 2018-01-31 2020-12-09 Canopy Holdings, Llc Hemp powder
US20210284621A1 (en) * 2018-05-31 2021-09-16 Corbus Pharmaceuticals, Inc. Cannabinoids and uses thereof
US11040932B2 (en) 2018-10-10 2021-06-22 Treehouse Biotech, Inc. Synthesis of cannabigerol
US20200121614A1 (en) * 2018-10-18 2020-04-23 Bluegrass Farmacueticals, LLC Cannabinoid-infused transparent hydrogel skin patch
WO2020183456A1 (en) * 2019-03-10 2020-09-17 Bol Pharma Ltd. Cannabinoid combinations for treating chronic pain in dialysis patients
JP2022551863A (ja) 2019-10-11 2022-12-14 コーバス ファーマシューティカルズ インコーポレーテッド アジュレミン酸の組成物及びその使用
US20220023253A1 (en) * 2020-07-21 2022-01-27 Np Pharma Holdings, Llc Cannabinoid Compositions and Methods for Treating Joint Pain and Inflammation

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2186485B (en) 1986-02-13 1988-09-07 Ethical Pharma Ltd Slow release formulation
US5338753A (en) 1992-07-14 1994-08-16 Sumner H. Burstein (3R,4R)-Δ6 -tetrahydrocannabinol-7-oic acids useful as antiinflammatory agents and analgesics
US6566560B2 (en) 1999-03-22 2003-05-20 Immugen Pharmaceuticals, Inc. Resorcinolic compounds
US8586767B2 (en) 1999-03-22 2013-11-19 Craig Rick Travis Method for treatment of HIV and diseases of immune dysregulation
US6974835B2 (en) 2000-05-17 2005-12-13 Indevus Pharmaceuticals, Inc. Methods for decreasing cell proliferation based on (3r,4r)-Δ8-tetrahydrocannabinol-11-oic acids
US7507767B2 (en) 2001-02-08 2009-03-24 Schering Corporation Cannabinoid receptor ligands
US7399872B2 (en) * 2001-03-07 2008-07-15 Webster G R Barrie Conversion of CBD to Δ8-THC and Δ9-THC
AU2003302578A1 (en) * 2002-12-04 2004-06-23 Pharmos Corporation High enantiomeric purity dexanabinol for pharmaceutical compositions
IL153277A0 (en) * 2002-12-04 2003-07-06 Pharmos Corp High enantiomeric purity dexanabinol for pharmaceutical compositions
US7413748B2 (en) 2002-12-13 2008-08-19 Purdue Pharma L.P. Transdermal buprenorphine to treat pain in sickle cell crisis
WO2004058251A1 (en) 2002-12-19 2004-07-15 University Of Massachusetts Cannabinoid analogs as peroxisome proliferator activated nuclear receptor gamma activators
US20050070596A1 (en) 2003-05-12 2005-03-31 David Baker Methods for treatment of inflammatory diseases using CT-3 or analogs thereof
US20050009903A1 (en) * 2003-06-10 2005-01-13 Martin Billy R. CB2-selective cannabinoid analogues
AU2006240490A1 (en) 2005-04-21 2006-11-02 Paladin Labs (Barbados) Inc. Process for the preparation of ultrapure 4-methylprazole
TWI366460B (en) * 2005-06-16 2012-06-21 Euro Celtique Sa Cannabinoid active pharmaceutical ingredient for improved dosage forms
US20070037873A1 (en) 2005-08-08 2007-02-15 Zurier Robert B Airway remodeling treatments
US20070060639A1 (en) 2005-09-09 2007-03-15 University Of Kentucky Compositions and methods for intranasal delivery of tricyclic cannabinoids
WO2007055806A1 (en) * 2005-10-31 2007-05-18 Indevus Pharmaceuticals, Inc. Anti-emetic uses of (3r,4r)-δ8-tetrahydrocannabinol-11-oic acids
GB2432312A (en) * 2005-11-01 2007-05-23 Gw Pharma Ltd Pharmaceutical compositions for the treatment of pain
DK1903866T3 (en) 2005-11-07 2016-07-25 Murty Pharmaceuticals Inc Improved release of tetrahydrocannabinol
US20080054300A1 (en) * 2006-06-30 2008-03-06 Philip Gene Nikkel Body contact structure and method for the reduction of drain lag and gate lag in field effect transistors
US8058227B2 (en) 2006-10-03 2011-11-15 Medical University Of South Carolina Method of treating fibrosis in a subject in need thereof comprising administering a composition comprising a CSD
US8044071B2 (en) 2007-10-18 2011-10-25 Abbott Laboratories Method for reducing side effects of CB2 receptor agonist therapy using a combination of a selective CB2 receptor agonist and a selective CB1 receptor antagonist
US9192598B2 (en) 2008-06-25 2015-11-24 University Of North Texas Health Science Center At Fort Worth Prevention of bacterial growth and biofilm formation by ligands that act on cannabinoidergic systems
US8877188B2 (en) 2010-05-04 2014-11-04 The Brigham And Women's Hospital, Inc. Detection and treatment of non-dermal fibrosis
US20130338220A1 (en) 2010-10-05 2013-12-19 Mark Tepper Compositions, dosages, and methods of using tetrahydrocannabinol derivatives
US20120309820A1 (en) 2011-06-04 2012-12-06 Jb Therapeutics Inc. Methods of treating fibrotic diseases using tetrahydrocannabinol-11-oic acids
JP6689078B2 (ja) 2013-02-12 2020-04-28 コーバス ファーマシューティカルズ インク． 超高純度なテトラヒドロカンナビノール−１１−酸
US20150328198A1 (en) 2014-05-16 2015-11-19 The University Of North Carolina At Chapel Hill Methods of treating methicillin-resistant staphylococcus aureus (mrsa) using ppar-gamma agonists

Also Published As

Publication number Publication date
JP6689078B2 (ja) 2020-04-28
CN105228613A (zh) 2016-01-06
JP2021185166A (ja) 2021-12-09
US9820964B2 (en) 2017-11-21
EP2956133A4 (en) 2016-12-21
US9801849B2 (en) 2017-10-31
US20150141501A1 (en) 2015-05-21
KR20190139327A (ko) 2019-12-17
US10369131B2 (en) 2019-08-06
US10154986B2 (en) 2018-12-18
AU2014216440B2 (en) 2018-08-09
AU2018258159B2 (en) 2020-01-02
WO2014127016A2 (en) 2014-08-21
AU2014216440A1 (en) 2015-08-20
CN110946854A (zh) 2020-04-03
AU2018258159A1 (en) 2018-11-22
US20170071900A1 (en) 2017-03-16
US20180177757A1 (en) 2018-06-28
US20170071899A1 (en) 2017-03-16
CA2900982A1 (en) 2014-08-21
US20220117931A1 (en) 2022-04-21
JP2016510340A (ja) 2016-04-07
EP3851101A1 (en) 2021-07-21
BR112015019180A8 (pt) 2018-01-30
CA2900982C (en) 2021-06-01
JP2019031505A (ja) 2019-02-28
EP2956133A2 (en) 2015-12-23
US20190091200A1 (en) 2019-03-28
US11052066B2 (en) 2021-07-06
US20200093784A1 (en) 2020-03-26
US10085964B2 (en) 2018-10-02
WO2014127016A3 (en) 2015-11-26
US20170071898A1 (en) 2017-03-16
BR112015019180A2 (pt) 2017-07-18

Similar Documents

Publication Publication Date Title
KR20160002709A (ko) 초고순도 테트라하이드로카나비놀-11-오익산
US20230100789A1 (en) Method for activating AMPK and the use of Adenine
AU2016207118B2 (en) Diphenyl derivative and uses thereof
AU2019203668B2 (en) Compound for activating AMPK and uses thereof
EP4346807A1 (en) Methods of use of ppar agonist compounds and pharmaceutical compositions thereof
CN105163732B (zh) 用于治疗眼科疾病和病症的方法
HK40026965A (en) Ultrapure tetrahydrocannabinol-11-oic acids
WO2012001053A1 (en) Metronidazole esters for treating rosacea
CN108546268B (zh) 用于治疗动脉粥样硬化的化合物及其应用
CN107823208A (zh) 吗啉类化合物在制备治疗和预防肾纤维化药物中的应用

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20150910

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20160212

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20161221

Patent event code: PE09021S01D

AMND Amendment
E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

Comment text: Final Notice of Reason for Refusal

Patent event date: 20171121

Patent event code: PE09021S02D

AMND Amendment
E601 Decision to refuse application
E801 Decision on dismissal of amendment
PE0601 Decision on rejection of patent

Patent event date: 20180713

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20171121

Comment text: Final Notice of Reason for Refusal

Patent event code: PE06011S02I

Patent event date: 20161221

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

PE0801 Dismissal of amendment

Patent event code: PE08012E01D

Comment text: Decision on Dismissal of Amendment

Patent event date: 20180713

Patent event code: PE08011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20180521

Patent event code: PE08011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20170721

AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20180713

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20180521

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20170721

Comment text: Amendment to Specification, etc.

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20181119

Patent event code: PE09021S01D

AMND Amendment
PX0601 Decision of rejection after re-examination

Comment text: Decision to Refuse Application

Patent event code: PX06014S01D

Patent event date: 20190906

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20190520

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20181119

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20181012

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20180713

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20180521

Comment text: Final Notice of Reason for Refusal

Patent event code: PX06013S02I

Patent event date: 20171121

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20170721

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20161221

J201 Request for trial against refusal decision
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20191206

PJ0201 Trial against decision of rejection

Patent event date: 20191206

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20190906

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Patent event date: 20180713

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20210316

Appeal identifier: 2019101004044

Request date: 20191206

J301 Trial decision

Free format text: TRIAL NUMBER: 2019101004044; TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20191206

Effective date: 20210316

PJ1301 Trial decision

Patent event code: PJ13011S01D

Patent event date: 20210316

Comment text: Trial Decision on Objection to Decision on Refusal

Appeal kind category: Appeal against decision to decline refusal

Request date: 20191206

Decision date: 20210316

Appeal identifier: 2019101004044